Colin Bristow
Stock Analyst at UBS
(1.66)
# 3,447
Out of 5,245 analysts
107
Total ratings
40.32%
Success rate
-4.44%
Average return
Main Sectors:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Therapeutics | Maintains: Neutral | $9 → $2 | $1.64 | +21.95% | 4 | May 14, 2026 | |
| NBTX Nanobiotix | Maintains: Neutral | $3.5 → $30 | $41.01 | -26.85% | 1 | May 1, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $434.52 | +25.66% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $134.36 | -16.64% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $68.81 | +16.26% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $2.96 | +68.92% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $1.98 | -49.49% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $34.15 | -50.22% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $339.30 | -5.98% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $2.51 | +59.36% | 4 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $28 | $25.90 | +8.11% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $122.41 | -1.97% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $193.76 | +4.25% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.13 | +1,315.93% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $638.88 | +72.02% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $16.80 | +894.05% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $1,065.00 | -60.56% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $11.46 | -82.55% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.75 | +928.57% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $215.70 | -32.31% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $59.46 | +26.14% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $3.56 | +630.34% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $7.99 | +12.64% | 1 | Aug 23, 2021 |
enGene Therapeutics
May 14, 2026
Maintains: Neutral
Price Target: $9 → $2
Current: $1.64
Upside: +21.95%
Nanobiotix
May 1, 2026
Maintains: Neutral
Price Target: $3.5 → $30
Current: $41.01
Upside: -26.85%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $434.52
Upside: +25.66%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $134.36
Upside: -16.64%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $68.81
Upside: +16.26%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $2.96
Upside: +68.92%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $1.98
Upside: -49.49%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $34.15
Upside: -50.22%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $339.30
Upside: -5.98%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $2.51
Upside: +59.36%
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $25.90
Upside: +8.11%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $122.41
Upside: -1.97%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $193.76
Upside: +4.25%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.13
Upside: +1,315.93%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $638.88
Upside: +72.02%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $16.80
Upside: +894.05%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $1,065.00
Upside: -60.56%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $11.46
Upside: -82.55%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $1.75
Upside: +928.57%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $215.70
Upside: -32.31%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $59.46
Upside: +26.14%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $3.56
Upside: +630.34%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $7.99
Upside: +12.64%